After ulcerative colitis flop, Immunic regains some momentum with multiple sclerosis update

Immunic has drummed up some enthusiasm for its multiple sclerosis candidate, highlighting the release of previously published data in a peer-reviewed journal and sharing an update on its next trial to claw back a sliver of the value it lost after its ulcerative colitis flop.